Abstracts tagged "uveitis and vasculitis"

Abstract Number: 2269 • 2018 ACR/ARHP Annual Meeting
Infliximab Therapy in Refractory Retinal Vasculitis of Behçet’s Disease, Short and Long-Term Follow-up. Multicenter Study of 72 Patients
José Luis Martín-Varillas¹, Belén Atienza-Mateo¹, Vanesa Calvo-Río², Diana Prieto Peña², Monica Calderón Goercke², Rosalía Demetrio-Pablo³, Javier Loricera³, M. Victoria Hernández⁴, Alfredo Adan⁵, Marina Mesquida⁵, Diana Peiteado⁶, David Diaz-Valle⁷, Lucía Martínez-Costa⁸, Elia Valls-Pascual⁸, Miguel A. Caracuel⁹, Angel Garcia-Aparicio¹⁰, Jose M Herreras¹¹, Miguel Cordero-Coma¹², Carlos Alberto Montilla-Morales¹³, Alejandro Fonollosa¹⁴, Antonio Atanes¹⁵, Félix Francisco¹⁶, Ignacio Torre-Salaberri¹⁷, Olga Maíz¹⁸, Ana Blanco¹⁹, Cruz Fernandez-Espartero²⁰, Norberto Ortego Centeno²¹, Enrique Raya Álvarez²², Myriam Gandía²³, Francisco Javier López Longo²⁴, Maria Alcalde-Villar²⁵, Cristina Fernández-Carballido²⁶, Esperanza Pato Cour²⁷, Oscar Ruiz Moreno²⁸, Fernando Jiménez-Zorzo²⁹, Raquel Almodóvar González³⁰, Carmen Carrasco-Cubero³¹, Luis Francisco Linares³², Fredeswinda I. Romero-Bueno³³, Santos Insua³⁴, Senen González-Suárez³⁵, Marisa Hernández³⁶, Emma Beltrán³⁷, Juan Cruz³⁸, Carlos Férnandez Cid³⁹, Elena Aurrecoechea⁴⁰, Enar Pons¹, Miguel Angel González-Gay³ and Ricardo Blanco¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²Rheumatology, Rheumatology. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ³Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ⁴Rheumatology, Hospital Clinic. Barcelona. Spain, Barcelona, Spain, ⁵Hospital Clinic. Barcelona. Spain, Barcelona, Spain, ⁶Rheumatology, Rheumatology, La Paz University Hospital, Madrid, Spain, ⁷Hospital Clínico San Carlos. Madrid. Spain, Madrid, Spain, ⁸Hospital Universitario Doctor Peset. Valencia. Spain, Valencia, Spain, ⁹Hospital de Córdoba, Córdoba, Spain., Córdoba, Spain, ¹⁰Rheumatology, Hospital de Toledo. Toledo. Spain, Toledo, Spain, ¹¹Ophthalmology, Hospital Universitario, IOBA. Valladolid. Spain, Valladolid, Spain, ¹²Ophthalmology, Hospital de León. Spain, León, Spain, ¹³Hospital Clínico Universitario de Salamanca. Spain, Salamanca, Spain, ¹⁴Ophthalmology, Hospital de Cruces. Bilbao. Spain, Bilbao, Spain, ¹⁵Complejo Hospitalario Universitario A Coruña. Spain, A Coruna, Spain, ¹⁶Rheumatology, Hospital Doctor Negrín. Las Palmas de Gran Canaria. Spain, Las Palmas de Gran Canaria, Spain, ¹⁷Rheumatology, Hospital Universitario de Basurto. Bilbao. Spain, Bilbao, Spain, ¹⁸Hospital Universitario Donostia. San Sebastian. Spain, San Sebastián, Spain, ¹⁹Ophtamology, Hospital Universitario Donostia. San Sebastian. Spain, San Sebastian, Spain, ²⁰Rheumatology, Hospital de Móstoles. Madrid. Spain, Madrid, Spain, ²¹Medicine Department, Hospital Universitario San Cecilio. Granada. Spain, Granada, Spain, ²²Rheumatology, Hospital Universitario San Cecilio. Granada. Spain, Granada, Spain, ²³Rheumatology, Hospital Puerta del Mar. Cádiz. Spain, Cádiz, Spain, ²⁴Rheumatology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²⁵Hospital Severo Ochoa, Madrid, Spain, Madrid, Spain, ²⁶Rheumatology Division, Hospital General Universitario de Elda, Elda, Spain, ²⁷Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ²⁸Ophthalmology and Rheumatology, Hospital Miguel Servet. Zaragoza. Spain, Zaragoza, Spain, ²⁹Hospital Miguel Servet. Zaragoza. Spain, Zaragoza, Spain, ³⁰Rheumatology, Hospital Universitario Fundación Alcorcón. Madrid. Spain, Madrid, Spain, ³¹Hospital de Mérida. Spain, Mérida, Spain, ³²Rheumatology, Hospital Virgen de la Arrixaca. Murcia. Spain, Murcia, Spain, ³³Section for Autoimmune Diseases, Rheumatology, Fundación Jiménez Díaz University Hospital & Health Research Institute, Madrid, Spain, ³⁴Rheumatology, Hospital Universitario Santiago de Compostela. La Coruña. Spain, La Coruña, Spain, ³⁵Rheumatology, Hospital de Cabueñes. Gijón. Spain, Gijón, Spain, ³⁶Ophthalmology, Hospital General Universitario de Valencia. Spain, Valencia, Spain, ³⁷Rheumatology, Hospital del Mar. Barcelona. Spain, Barcelona, Spain, ³⁸Hospital de Pontevedra. Pontevedra. Spain, Pontevedra, Spain, ³⁹Ophthalmology, Hospital de Pontevedra. Pontevedra. Spain, Pontevedra, Spain, ⁴⁰Rheumatology, Hospital de Sierrallana, Torrelavega. Cantabria. Spain, Torrelavega, Spain
Background/Purpose: Retinal vasculitis is a serious complication of uveitis due to Behçet’s disease (BD). The treatment is based on corticosteroids, conventional immunosuppressants (IS) and anti-TNF-α…
Abstract Number: 2150 • 2016 ACR/ARHP Annual Meeting
Autoimmune Uveitis : Potential Role of Interleukin-22 (IL-22) in Pathogenesis
El-Desouki Fouda¹, El-Sayed Mostafa Elewah², Mona Elrayes³, Ghada Fouda⁴ and Mohamed Ahmed Bakry⁵, ¹Al-Azhar University, Dokki Cairo, Egypt, ²Opthalmology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt, ³Clinical Pathology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt, ⁴Faculty of Medicine, Al-Azhar University, Cairo, Egypt, ⁵Al-Azhar University, Allergy & Immunology Center, Cairo, Egypt
Background/Purpose: : IL-22 is a member of IL-10 family, with both anti- inflammatory and pro- inflammatory functions, orchestrating the immune and inflammatory response.IL-22 is secreted…
Abstract Number: 2760 • 2014 ACR/ARHP Annual Meeting
Interferon Alfa-Associated Depression in Patients with Behçet’s Syndrome
Yasin Keskin¹, Emire Seyahi², Cagri Poyraz³, Serdal Ugurlu¹, Yilmaz Ozyazgan⁴ and Hasan Yazici⁵, ¹Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ²Division of Rheumatology,Department of Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ³Department of Psychiatry, Cerrahpasa Medical Faculty, University Of Istanbul, Istanbul, Istanbul, Turkey, ⁴Department of Ophthalmology, Cerrahpasa Medical Faculty University of Istanbul, Istanbul, Turkey, ⁵Istanbul University, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey
Background/Purpose: Interferon (IFN) is an effective immune-modulatory agent in the medical management of eye disease of Behçet’s syndrome (BS). The agent is frequently associated with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].